Genomma Lab Internacional Stock Fundamentals
| GNMLF Stock | USD 1.27 0.00 0.00% |
Genomma Lab Internacional fundamentals help investors to digest information that contributes to Genomma Lab's financial success or failures. It also enables traders to predict the movement of Genomma Pink Sheet. The fundamental analysis module provides a way to measure Genomma Lab's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Genomma Lab pink sheet.
Genomma |
Genomma Lab Internacional Company Profit Margin Analysis
Genomma Lab's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Genomma Lab Profit Margin | 0.08 % |
Most of Genomma Lab's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Genomma Lab Internacional is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, Genomma Lab Internacional has a Profit Margin of 0.081%. This is 100.72% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The profit margin for all United States stocks is 106.38% lower than that of the firm.
Genomma Lab Internacional Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Genomma Lab's current stock value. Our valuation model uses many indicators to compare Genomma Lab value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Genomma Lab competition to find correlations between indicators driving Genomma Lab's intrinsic value. More Info.Genomma Lab Internacional is rated below average in return on equity category among its peers. It is one of the top stocks in return on asset category among its peers reporting about 0.73 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Genomma Lab Internacional is roughly 1.37 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Genomma Lab's earnings, one of the primary drivers of an investment's value.Genomma Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Genomma Lab's direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Genomma Lab could also be used in its relative valuation, which is a method of valuing Genomma Lab by comparing valuation metrics of similar companies.Genomma Lab is currently under evaluation in profit margin category among its peers.
Genomma Fundamentals
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0921 | |||
| Profit Margin | 0.08 % | |||
| Operating Margin | 0.20 % | |||
| Current Valuation | 1.09 B | |||
| Shares Outstanding | 1 B | |||
| Shares Owned By Insiders | 29.00 % | |||
| Shares Owned By Institutions | 29.10 % | |||
| Price To Earning | 11.09 X | |||
| Price To Book | 1.38 X | |||
| Price To Sales | 0.05 X | |||
| Revenue | 15.49 B | |||
| Gross Profit | 9.56 B | |||
| EBITDA | 2.84 B | |||
| Net Income | 1.31 B | |||
| Cash And Equivalents | 1.3 B | |||
| Cash Per Share | 1.30 X | |||
| Total Debt | 3.83 B | |||
| Debt To Equity | 0.51 % | |||
| Current Ratio | 1.67 X | |||
| Book Value Per Share | 10.98 X | |||
| Cash Flow From Operations | 1.47 B | |||
| Earnings Per Share | 0.07 X | |||
| Number Of Employees | 2.3 K | |||
| Beta | 0.53 | |||
| Market Capitalization | 973.77 M | |||
| Total Asset | 21.54 B | |||
| Annual Yield | 0.05 % | |||
| Net Asset | 21.54 B | |||
| Last Dividend Paid | 0.38 |
About Genomma Lab Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Genomma Lab Internacional's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Genomma Lab using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Genomma Lab Internacional based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, engages in the development, marketing, and sale of over-the-counter pharmaceutical and personal care products in Mexico and internationally. Genomma Lab Internacional, S.A.B. de C.V. was incorporated in 1996 and is based in Mexico City, Mexico. Genomma Lab operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 2327 people.
Currently Active Assets on Macroaxis
Other Information on Investing in Genomma Pink Sheet
Genomma Lab financial ratios help investors to determine whether Genomma Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Genomma with respect to the benefits of owning Genomma Lab security.